Detalles de la búsqueda
1.
Multimethod quantitative benefit-risk assessment of treatments for moderate-to-severe osteoarthritis.
Br J Clin Pharmacol
; 88(8): 3837-3846, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35277997
2.
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.
Ann Rheum Dis
; 79(6): 800-810, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32234715
3.
Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera.
Ann Rheum Dis
; 81(4): e66, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32424029
4.
A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan.
Pharmaceut Med
; 38(3): 217-224, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38555545
5.
Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?
Eur J Pain
; 25(7): 1525-1539, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33728717
6.
Satisfaction, Adherence and Health-Related Quality of Life with Transdermal Buprenorphine Compared with Oral Opioid Medications in the Usual Care of Osteoarthritis Pain.
Patient
; 9(4): 359-71, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27314487
7.
Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review.
Clin Ther
; 37(1): 212-24, 2015 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25592091
Resultados
1 -
7
de 7
1
Próxima >
>>